Once daily insulin detemir in cystic fibrosis with insulin deficiency

Archives of Disease in Childhood

Volumn 97, Issue 5, 2012, Pages 464-467

  Hameed, Shihab ^a,b   Morton, John R ^a,b   Field, Penny I ^a   Belessis, Yvonne ^a,b   Yoong, Terence ^a   Katz, Tamarah ^a   Woodhead, Helen J ^a,b   Walker, Jan L ^a,b   Neville, Kristen A ^a,b   Campbell, Thomas A ^a   Jaffé, Adam ^a,b   Verge, Charles F ^a,b  

^a SYDNEY CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN DETEMIR;

ADOLESCENT; ADULT; ARTICLE; BODY WEIGHT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CYSTIC FIBROSIS; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INSULIN DEFICIENCY; LUNG FUNCTION; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADOLESCENT; BLOOD GLUCOSE; BLOOD GLUCOSE SELF-MONITORING; CHILD; CYSTIC FIBROSIS; DIABETES MELLITUS; DRUG ADMINISTRATION SCHEDULE; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; INSULIN, LONG-ACTING; MALE; PREDIABETIC STATE; TREATMENT OUTCOME; VITAL CAPACITY; WEIGHT GAIN;

EID: 84860331004     PISSN: 00039888     EISSN: 14682044     Source Type: Journal    
DOI: 10.1136/adc.2010.204636     Document Type: Article

References (7)

1. Moran A, Pekow P, Grover P, et al. Insulin therapy to improve BMI in cystic fibrosis-related diabetes without fasting hyperglycemia: results of the cystic fibrosis related diabetes therapy trial. Diabetes Care 2009;32:1783-8.
2. Hameed S, Morton JR, Jaffé A, et al. Early glucose abnormalities in cystic fibrosis are preceded by poor weight gain. Diabetes Care 2010;33:221-6.
3. Mozzillo E, Franzese A, Valerio G, et al. One-year glargine treatment can improve the course of lung disease in children and adolescents with cystic fibrosis and early glucose derangements. Pediatr Diabetes 2009;10:162-7.
4. Bizzarri C, Luci di V, Ciampalini P, et al. Clinical effects of early treatment with insulin glargine in patients with cystic fibrosis and impaired glucose tolerance. J Endocrinol Invest 2006;29:RC1-4.
5. Heise T, Nosek L, Rønn BB, et al. Lower within-subject variability of insulin detemir in comparison to NPH insulin and insulin glargine in people with type 1 diabetes. Diabetes 2004;53:1614-20. (Pubitemid 38697678)
6. Danne T, Datz N, Endahl L, et al. Insulin detemir is characterized by a more reproducible pharmacokinetic profile than insulin glargine in children and adolescents with type 1 diabetes: results from a randomized, double-blind, controlled trial. Pediatr Diabetes 2008;9:554-60.
7. Dobson L, Hattersley AT, Tiley S, et al. Clinical improvement in cystic fibrosis with early insulin treatment. Arch Dis Child 2002;87:430-1. (Pubitemid 35252911)